A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants with Unresectable Pleural Mesothelioma (eVOLVE-Meso)
Details
Age
Adult
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Tejas Patil
Study ID
Protocol Number: 24-0442
More information available at ClinicalTrials.gov: NCT06097728
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers